JP2013535477A5 - - Google Patents

Download PDF

Info

Publication number
JP2013535477A5
JP2013535477A5 JP2013522132A JP2013522132A JP2013535477A5 JP 2013535477 A5 JP2013535477 A5 JP 2013535477A5 JP 2013522132 A JP2013522132 A JP 2013522132A JP 2013522132 A JP2013522132 A JP 2013522132A JP 2013535477 A5 JP2013535477 A5 JP 2013535477A5
Authority
JP
Japan
Prior art keywords
polyethylene glycol
noge
emissions
mpa
ion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013522132A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013535477A (ja
JP5937593B2 (ja
Filing date
Publication date
Priority claimed from EP10008104A external-priority patent/EP2415460A1/de
Application filed filed Critical
Publication of JP2013535477A publication Critical patent/JP2013535477A/ja
Publication of JP2013535477A5 publication Critical patent/JP2013535477A5/ja
Application granted granted Critical
Publication of JP5937593B2 publication Critical patent/JP5937593B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013522132A 2010-08-03 2011-08-02 プレガバリンの経口投与剤形 Active JP5937593B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10008104.1 2010-08-03
EP10008104A EP2415460A1 (de) 2010-08-03 2010-08-03 Orale Darreichungsform von Pregabalin
PCT/EP2011/003873 WO2012016683A2 (en) 2010-08-03 2011-08-02 Oral dosage form of pregabalin

Publications (3)

Publication Number Publication Date
JP2013535477A JP2013535477A (ja) 2013-09-12
JP2013535477A5 true JP2013535477A5 (enExample) 2016-02-18
JP5937593B2 JP5937593B2 (ja) 2016-06-22

Family

ID=43216378

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013522132A Active JP5937593B2 (ja) 2010-08-03 2011-08-02 プレガバリンの経口投与剤形

Country Status (6)

Country Link
US (1) US20130149253A1 (enExample)
EP (2) EP2415460A1 (enExample)
JP (1) JP5937593B2 (enExample)
KR (1) KR20140003376A (enExample)
CA (1) CA2806752A1 (enExample)
WO (1) WO2012016683A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013100874A1 (en) * 2011-12-19 2013-07-04 Mahmut Bilgic Effervescent pregablin formulation
WO2013109199A1 (en) * 2011-12-19 2013-07-25 Mahmut Bilgic Effervescent pharmaceutical formulations comprising pregabalin and vitamin b12
WO2013100873A1 (en) * 2011-12-19 2013-07-04 Mahmut Bilgic Pharmaceutical formulation of pregabalin (particle size 300-2500 micrometer)
MX2013001278A (es) * 2013-01-31 2014-07-30 Miguel Ángel García Pérez Composicion farmaceutica con un sistema bifasico de liberacion inmediata para el control de eventos convulsivos y del dolor.
WO2015114655A2 (en) * 2014-01-21 2015-08-06 Intas Pharmaceuticals Limited Modified release tablet of pregabalin
PL235144B1 (pl) * 2014-06-03 2020-06-01 Univ Medyczny Im Piastow Slaskich We Wroclawiu Sposób wytwarzania tabletki flotacyjnej o przedłużonym oddziaływaniu substancji leczniczych z błoną śluzową żołądka oraz kompozycja farmaceutyczna
CN104561442B (zh) * 2014-10-23 2017-05-31 东莞市佳平装饰材料有限公司 一种核电用347奥氏体不锈钢的制备方法
CN111840239B (zh) * 2014-10-24 2022-11-18 江苏恒瑞医药股份有限公司 一种普瑞巴林缓释制剂
JP6919119B2 (ja) * 2017-01-23 2021-08-18 日新製薬株式会社 ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
KR102039345B1 (ko) * 2017-02-01 2019-11-01 지엘팜텍주식회사 프레가발린 함유 고팽윤성 서방성 삼중정제
KR102039344B1 (ko) * 2017-02-01 2019-11-01 지엘팜텍주식회사 프레가발린 함유 경구용 서방성 삼중정제
WO2022017364A1 (zh) * 2020-07-20 2022-01-27 四川海思科制药有限公司 一种稠合三环γ-氨基酸衍生物的缓释药物制剂及其制备方法
CN112245404A (zh) * 2020-11-02 2021-01-22 成都晶富医药科技有限公司 一种普瑞巴林胶囊及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2134674C (en) 1992-05-20 2004-12-21 Richard B. Silverman Gaba and l-glutamic acid analogs for antiseizure treatment
EE200100153A (et) * 1998-09-14 2002-06-17 Ranbaxy Laboratories Limited Kontrollitav ravimiväljutussüsteem ravimite suukaudseks manustamiseks, mis pakub ajalist ja ruumilist kontrolli
CA2356829A1 (en) * 2000-09-22 2002-03-22 Warner-Lambert Company Method for treating asthma using pregabalin
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
CA2491665A1 (fr) * 2004-12-24 2006-06-24 Louis Cartilier Formulation de comprime pour liberation soutenue de principe actif
US20070092565A1 (en) * 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
EP1957052A2 (en) * 2005-10-25 2008-08-20 Pharmascience Inc. A gastric retention drug delivery system
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
CA2635466A1 (en) * 2005-12-29 2007-07-12 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
EP2068844A4 (en) * 2006-09-04 2013-01-23 Panacea Biotec Ltd PROGRAMMABLE RELEASE TECHNIQUE BY FLOATING SYSTEM
WO2008076458A1 (en) * 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
WO2010035273A2 (en) * 2008-09-29 2010-04-01 Intec Pharma Ltd. Novel gastroretentive delivery system
US20120065221A1 (en) * 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
EP2736499B1 (en) * 2011-07-26 2016-05-11 Yuhan Corporation Sustained release tablet comprising pregabalin through two-phase release-controlling system

Similar Documents

Publication Publication Date Title
JP2013535477A5 (enExample)
CN109072050A (zh) 一种高效环保型抑尘剂及其制备方法、应用
JP2018040002A5 (enExample)
HRP20180965T1 (hr) Formulacija lijeka s produženim otpuštanjem
JP2016525572A5 (enExample)
IL225640A (en) Benzimidazole Derivatives, Pharmaceutical Preparations Containing Them, Processes for their Preparation and Uses as Respiratory Systemic Viral Inhibitors
EP2600849A4 (en) FILM-FORMING COMPOSITION FOR SOFT CAPSULES
WO2017155286A3 (ko) 2,5-퓨란디카르복시산 제조용 촉매 및 이 촉매를 이용한 2,5-퓨란디카르복시산의 제조방법
CL2014000468A1 (es) Compuestos derivados del acido 2-oxo-6-(fenil/heteroaril)l-1,2-dihidropiridin-3-carboxilico; composicion farmaceutica; combinacion; y su uso para el alivio de una infeccion bacteriana.
WO2010084157A8 (en) Multifunctional stealth nanoparticles for biomedical use
JP2013010803A5 (enExample)
WO2012021715A3 (en) Stable formulations of linaclotide
WO2010082220A3 (en) Sustained release pharmaceutical composition of quetiapine and process for preparation thereof
JP2017520577A5 (enExample)
NZ603531A (en) Alcohol-resistant formulations
JP2012031240A5 (enExample)
JP2016529286A5 (enExample)
MX2012001691A (es) Composiciones de linaclotida que se desintegran oralmente.
IN2014DE00037A (enExample)
JP2014122166A5 (enExample)
JP2013216719A5 (enExample)
JP2011513393A5 (enExample)
TN2012000431A1 (en) Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant
WO2007100822A3 (en) Fluvastatin sodium pharmaceutical compositions
WO2012117115A3 (de) Verwendung eines viskoelastischen fluids zur herstellung eines medizinproduktes für die chirurgische behandlung des auges